Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, raising intracellular sodium. This change reduces the sodium‑calcium exchanger activity, leading to calcium buildup inside the cells, which strengthens heart contractions. At the same time, digoxin enhances vagal tone, slowing the heart rate and helping to regulate abnormal rhythms.

The appropriate dose of Lanoxin is individualized by the prescribing clinician based on the patient’s age, weight, renal function, electrolyte status and therapeutic goals. Dosage adjustments are made after evaluating serum digoxin concentrations and clinical response; no fixed regimen can be stated without a medical prescription.

The pregnancy safety category for digoxin is not definitively established. Use during pregnancy or lactation is reserved for situations where the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss uncertainties and consider alternative therapies when possible.

To request Lanoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Lanoxin (digoxin) belongs to the cardiac glycoside class, whereas alternatives such as milrinone are phosphodiesterase‑3 inhibitors and amiodarone is a class III antiarrhythmic. Digoxin provides both inotropic support and rate control, while milrinone offers pure inotropy without significant rate‑slowing, and amiodarone primarily addresses rhythm conversion without enhancing contractility.

Lanoxin must be stored at 2 °C to 8 °C, protected from light, and never frozen or shaken. The product should remain in its original container until use, and any unused portion should be discarded according to local regulations for injectable medicines.

Lanoxin is supplied as an injectable solution for intravenous administration. It is typically given as a slow IV push or infusion under clinical supervision, with dosing calculated by the prescriber. Continuous cardiac monitoring is recommended during and after administration to detect any adverse rhythm changes.

The most critical risks include life‑threatening cardiac arrhythmias such as ventricular tachycardia, severe bradycardia or heart block, and visual disturbances like yellow‑green halos that may signal toxicity. Early recognition of nausea, vomiting or electrolyte imbalance is essential, and serum digoxin levels should be monitored regularly.

Lanoxin is contraindicated in patients with ventricular fibrillation, known hypersensitivity to digoxin or other cardiac glycosides, and in those with severe conduction disorders such as high‑grade AV block without a pacemaker. Caution is also advised for individuals with significant renal impairment, uncontrolled electrolyte disturbances, or thyroid disease.